Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Vertex HIV Drug Candidate Development Halted by GlaxoSmithKline Because of Formulation Problem

December 22, 2006

GlaxoSmithKline has stopped collaborating with Vertex Pharmaceuticals Inc. on the HIV drug candidate brecanavir (VX-385), Vertex said in a recent Securities and Exchange Commission filing. The drug, which was in mid-stage clinical testing, would be too difficult to formulate, said Glaxo. The firms have collaborated since 1993, yielding the HIV treatments Agenerase and Lexiva.

Back to other news for December 22, 2006

Adapted from:
Associated Press
12.18.2006


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement